Prevalence and Management of Lymphedema in Urogenital Cancers

Lymphedema with regards to women’s health is most commonly associated with breast cancer. Upper extremity lymphedema can be limiting and painful without a doubt, and I have seen women suffering from irritating edema and limited shoulder range of motion and function after radical mastectomy. However, we may not always consider lower extremity lymphedema which can occur as a result of urogenital cancers and their treatments. Our knowledge and skilled hands can impact the quality of life of these patients who may seek treatment for their post-cancer complications.

Mitra et al., published a 2016 retrospective study on lymphedema risk post radiation therapy in endometrial cancer. They considered 212 endometrial cancer survivors, and 7.1% who received adjuvant pelvic radiation therapy developed lower extremity lymphedema after treatment, whether they had chemotherapy or not. Finding at least 1 positive pathological lymph node was directly correlated with an increased risk of lymphedema, regardless of attempts to control pelvic lymph-node dissection. These statistics encourage finding prophylactic measures to take for stage III endometrial cancer patients to minimize the risk for long-term lymphedema. Regarding treatment for lower extremity lymphedema, this paper discussed compression stocking use, pneumatic compression stockings, and complex decongestive therapy, an intensive regimen of physical therapy and massage that is unfortunately not easily accessible for a majority of patients. The authors encouraged future research on the efficacy of exercise and compression for lymph node positive patients.

Shaitelman et al. presented a review of the progress made in the treatment and prevention of cancer-related lymphedema (2015). They stated gynecologic cancer treatment is associated with 25% incidence of lymphedema. Endometrial cancer had 1%, cervical cancer had 27%, and vulvar cancer had 30% incidence specifically. Sentinel lymph node biopsy (SLNB) can be an important part of cancer treatment, as lymphedema incidence was shown to average 9%. With treatment of genitourinary cancers, lymphedema occurred in 4% patients with prostate cancer, 16% patients with bladder cancer, and 21% patients with penile cancer. Shown to decrease limb volume and improve quality of life, the current standard of care is complete decongestive therapy (CDT). These authors state CDT involves the use of manual lymphatic drainage (MLD), bandaging on a daily basis, skin care, exercise, and a 3-phase protocol of compression. The use of SLNB helps identify the risk of lymphedema post cancer treatment; however, clinicians need to be aware of the signs and symptoms of lymphedema so the affected patient can be recognized early and referred to the appropriate specialist for treatment.

We may be referred patients with the confirmed diagnosis of lymphedema, but often we see post-cancer patients for rehab who develop lymphedema months after radiation or chemotherapy. Any healthcare professional involved with regular treatment of a cancer-surviving patient needs to have a keen sense for diagnosing and properly taking care of lymphedema. Courses such as “Lymphatics and Pelvic Pain: New Strategies” can open a whole new avenue for understanding what patients may need from us following urogenital and genitourinary cancers. Why not be prepared to face with knowledge and skill whatever pathology our patients present?

Mitra, D., Catalano, P.J., Cimbak, N., Damato, A.L., Muto, M.G., & Viswanathan, A.N. (2016). The Risk of Lymphedema After Postoperative Radiation Therapy in Endometrial Cancer. Journal of Gynecologic Oncology, 27(1), e4.
Shaitelman, S.F., Cromwell, K.D., Rasmussen, J.C., Stout, N.L., Armer, J.M., Lasinski, B.B., & Cormier, J.N. (2015). Recent Progress in Cancer-Related Lymphedema Treatment and Prevention. CA: A Cancer Journal for Clinicians, 65(1), 55-81.